Johnson & Johnson Sunscreen

This docket consolidated claims tied to a 2021 recall of certain Johnson & Johnson sunscreen products after internal testing detected trace levels of benzene, a known carcinogen, in some aerosol sunscreen lots, prompting both economic-loss claims from purchasers and personal-injury claims alleging that use of the recalled products contributed to skin cancer or other conditions. As of the JPML's September 2026 report, the docket shows zero actions currently pending against sixteen total actions ever filed — a docket that has effectively wound down to nothing from an original population that was already small relative to many mass torts.

For a funder, a docket at zero pending actions is not a funding target in any conventional sense. Whatever claim volume existed here appears to have been resolved, dismissed, or otherwise closed out, and there is no active claims pipeline, settlement-fund distribution, or bellwether track to evaluate. Any residual interest would need to start from confirming whether a specific, newly filed or reopened claim exists at all before any funding conversation is relevant — this is fundamentally different from a docket carrying a live but small residual population.

Where this docket still has value is as a comparison point: a benzene-contamination recall claim of this kind evidently did not develop into the kind of large, durable claims population that has characterized other consumer-product and pharmaceutical recalls, and understanding why — whether through early dismissal, individual settlement, or a thin underlying injury theory — is useful context for evaluating a newer recall-driven filing with superficially similar facts. Criterica Capital's mass tort finance line is not presently a relevant fit for this docket given its current inactive status, and a structural brief on its short procedural history is available through Criterica Intelligence for firms doing comparative diligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.